Hot topics in vaccine science

Our Clinical Vaccinology Update (CVU) mini’s are a series of webinar sessions for health care professionals. Each CVU mini will provide information on the latest in vaccine news and clinical updates from a range of presenters.

Update: At our upcoming CVU mini there will also be an opportunity to hear the latest update on vaccine safety concerns around clotting syndromes associated with the COVID-19 AstraZeneca vaccine.

Event details:
Date: Monday 12th April, 2021
Time: 7pm – 8:30pm AEDT

This is a FREE event and will be held via Zoom.

WordPress Tables Plugin

Presenters

Dr Daryl Cheng
MBBS, MPH, FRACP Medical Advisor, Melbourne Vaccine Education Centre

Dr Cheng is a general paediatrician who works at The Royal Children’s Hospital and Monash Children’s Hospital. He is a Senior Research Fellow at Murdoch Children’s Research Institute. He has special interests in immunisation, education and health informatics.

Professor Ian Barr
Deputy Director, WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia

Professor Ian Barr is Deputy Director of the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza. Ian has had over 35 years’ experience in biological research and development in academic institutions and at CSL Limited on various topics such as vaccine development, mucosal immunology, adjuvants, cancer therapeutics, immune system development and diagnostics. Ian joined the Centre in 2000 and has served as Deputy Director since 2005. He is an Honorary Senior Research Fellow at Federation University and holds an honorary position at the University of Melbourne.

Professor Michael Gold
Professor, Adelaide Medical School, Faculty of Health and Medical Sciences, Adelaide, Australia       

Professor Michael Gold is a paediatric ​allergy and immunology specialist and senior lecturer in paediatrics at the University of Adelaide, South Australia. His research and clinical interests ​focus on the areas of childhood food allergy and vaccine safety. In 2010, he was the first Australian appointed to the World Health ​Organization (WHO) Global Advisory Committee for Vaccine Safety. He has been an expert vaccine advisor to the Therapeutic Goods Administration (TGA) since 2006. He is a member of the Australasian Society of Clinical Immunology (ASCIA) and the medical board of Allergy Anaphylaxis Australia

Professor Paul Heath
Professor of Paediatric Infectious Diseases, St George’s University of London & St George’s University Hospitals NHS Trust, London

Paul Heath is a Professor and Honorary Consultant in Paediatric Infectious Diseases at St George’s University Hospitals NHS Foundation Trust and St George’s, University of London, where he co-leads the Paediatric Infectious Diseases Research Group and is the Director of the Vaccine Institute. His training in paediatrics and infectious diseases was at the Royal Children’s Hospital, Melbourne, Australia, the John Radcliffe Hospital, Oxford and St George’s Hospital, London. His particular research interests are in the epidemiology of vaccine preventable diseases, in clinical vaccine trials, particularly in at-risk groups and in perinatal infections, and he has over 300 publications in these areas. He coordinates a European neonatal infection surveillance network (neonIN: https://www.neonin.org.uk) and the UK Paediatric Vaccine Group (UKPVG), and other recent work includes national surveillance on neonatal meningitis, neonatal GBS and Listeria infections, maternal immunisation trials, studies of different vaccine schedules in preterm infants and COVID-19 vaccine trials (Phase I-III). He sits on national UK committees concerned with meningitis, Group B streptococcus prevention, immunisation policies in children and COVID-19 vaccine trial delivery. He is Chair of the Research Committee of the European Society of Paediatric Infectious Diseases, Section Editor of the Pediatric Infectious Diseases Journal (maternal & neonatal), Clinical Lead for Children’s research for South London and a member of the WHO GBS Surveillance Technical Working Group.